A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Completed · Phase 3 · NCT05171855
Conditions: Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
At a glance
- Research payments reported, 2025
- $281,882
- U.S. investigators named
- 13
- Sites paid
- 15
- Planned or actual enrollment
- 220
About the trial
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Tested
- Lonapegsomatropin (drug)
- Dates
- Started 2021-12-16; completion 2024-12-23
- Results posted
- Yes
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
From ClinicalTrials.gov, last updated 2026-07-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ascendis Pharma Endocrinology Inc reported $281,882 in research payments for this study in 2025 (61 payments).
Products named: Skytrofa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kevin C. Yuen, MBCHB, MD, FRCPUK Endocrinology & Diabetes · Phoenix, AZ
- Wenyu Huang, M.D., PH.D. Endocrinology & Diabetes · Chicago, IL
- Beverly M. Biller, MD Endocrinology & Diabetes · Boston, MA
- Opada Alzohaili, MD Endocrinology & Diabetes · Dearborn, MI
- Irina Bancos, M.D. Endocrinology & Diabetes · Rochester, MN
- Julie M. Silverstein, MD Endocrinology & Diabetes · Saint Louis, MO
- Samer Nakhle, MD Endocrinology & Diabetes · Las Vegas, NV
- Nidhi Agrawal Endocrinology & Diabetes · New York, NY
- Georgiana A. Dobri, MD Endocrinology & Diabetes · New York, NY
- Maria Fleseriu, MD Endocrinology & Diabetes · Portland, OR
- Oksana Hamidi, D.O. Endocrinology & Diabetes · Dallas, TX
- Daniel Katselnik, MD Endocrinology & Diabetes · Shavano Park, TX
- Jose M. Garcia, MD, PHD Endocrinology & Diabetes · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Lundquist Institute $66,282
- NYU School of Medicine $54,272
- Weill Cornell Medical College $28,636
- Mayo Clinic $24,690
- St Josephs Hospital and Medical Center, AZ $23,089
- Consano Clinical Research, LLC $14,387
- Northwestern University $12,980
- Seattle Institute for Biomedical and Clinical Research $10,550
- The University of Texas Southwestern Medical Center $10,189
- Washington University $9,825
- Massachusetts General Hospital, MA $7,700
- Palm Research Center Inc $7,125
- Ohsu Hospital and Clinics, OR $6,408
- Biomedical Research Alliance of New York LLC (brany) $4,750
- Veritas Research Group LLC $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.